TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03886233
Drug: Corticosteroid Series
Normalized name: Corticosteroid series
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Study: NCT03226392
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 once daily
Study: NCT03226392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00661219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
Study: NCT01972178
Drug: PRC-4016
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01972178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00076609
Drug: PHY906
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00076609
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03410537
Drug: Taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03410537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01975480
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00732693
Drug: Ethinylestradiol / Norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days
Study: NCT00732693
Drug: Estradiol / Progesterone
Normalized name: estradiol / progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
Study: NCT01960842
Drug: Levodopa-carbidopa intestinal gel
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Study: NCT03648970
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participant will be given pravastatin 2 x 20 mg per oral daily
Study: NCT02002208
Drug: OC000459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CRTH2 antagonist
Study: NCT03128164
Drug: HMPL-689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
Study: NCT01406431
Drug: Livalo® fixed combination drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livalo® fixed combination drug(1 tablet)
Study: NCT03865680
Drug: CPP-ACP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Study: NCT01691742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
Study: NCT01691742
Drug: Rescue Laxative
Normalized name: Pore Rescue
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
Study: NCT02943720
Drug: AllerT
Normalized name: AllerTan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
Study: NCT02943720
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02734446
Drug: Reuterin D3 drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 drops/day for 3 months
Study: NCT04025307
Drug: bacTRL-IL-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
Study: NCT01362374
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT03791476
Drug: rhC1INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor
Study: NCT03472469
Drug: Acetaminophen IV/PO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g IV/PO every 6 hours
Study: NCT03472469
Drug: Acetaminophen PO
Normalized name: ACETAMINOPHEN POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g PO every 6 hours
Study: NCT03472469
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 30mg IV once
Study: NCT03472469
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg PO every 12 hours
Study: NCT03472469
Drug: Opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
Study: NCT03472469
Drug: Regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthesia
Study: NCT02402543
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02826031
Drug: DICL-SR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02843386
Drug: Adjuvant chemotherapy by Fotemustin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fotemustin is given for 6 cycles :~* One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~* Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.
Study: NCT01342146
Drug: Jintropin AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg/wk, once a day for 25 weeks
Study: NCT01741701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03251820
Drug: corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will be subjected to a one month course of steroids and then re-evaluated
Study: NCT00927186
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension.
Study: NCT03108027
Drug: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Study: NCT03108027
Drug: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Study: NCT03108027
Drug: Treatment C: Placebo (morning dose) and placebo (evening dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (morning dose) and placebo (evening dose)
Study: NCT01727973
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab. Doxycycline 50 mg PO per day for 12 weeks
Study: NCT01750281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three placebo capsules will be administered orally uninterrupted twice daily.
Study: NCT01421134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02765971
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C received 500 cc of normal saline, Intravenous fluid
Study: NCT02306785
Drug: TP05 Coating E
Approvals — FDA: no, EMA: no, PMDA: no
Description: One radio-labelled tablet given to subjects
Study: NCT02306785
Drug: TP05 Coating H
Approvals — FDA: no, EMA: no, PMDA: no
Description: One radio-labelled tablet given to subjects
Study: NCT03394807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection to Transversus abdominis plane and rectus sheath
Study: NCT01104298
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
Study: NCT02663570
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01619683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule per day, oral
Study: NCT01009242
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individual stable doses of methotrexate.
Study: NCT04517799
Drug: placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.
Study: NCT01290731
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg capsule once daily for 12 weeks
Study: NCT00601107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01271660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
Study: NCT01910090
Drug: FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET
Normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MULTI-LAYER TABLET
Study: NCT01910090
Drug: ANTADYS® 100 mg, PEPCID® 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
Study: NCT01730209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00262808
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00262808
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00933374
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
Study: NCT03119194
Drug: [14C]-BIA 9-1067
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × 100 mg capsule, Oral
Study: NCT01181128
Drug: Advate®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02060149
Drug: C/S plus minocycline.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
Study: NCT02060149
Drug: nebulization with pH 7.4 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
Study: NCT02060149
Drug: nebulization with pH 7.8 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
Study: NCT02060149
Drug: No nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nebulization will be given to the patients.
Study: NCT01330589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active placebo for 7 days: PO/TID
Study: NCT02532790
Drug: ACEI
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2-0.3mg/kg/d
Study: NCT01858090
Drug: Control Group Chirocaine
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
Study: NCT01858090
Drug: Group Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01858090
Drug: Group sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858090
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: as additional analgesic among cases in which VAS\>3(Postoperatively)
Study: NCT00268996
Drug: SB-480848 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is available as enteric-coated, free-base micronized tablet
Study: NCT00533845
Drug: On-Q Pain Pump
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
Study: NCT03676933
Drug: DS107E
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676933
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676933
Drug: Hydrocortisone Butyrate 0.1% Cream
Normalized name: HYDROCORTISONE BUTYRATE 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid taken topically once a day
Study: NCT01986660
Drug: Ibuprofen Cream (SST-0225)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01521455
Drug: HCP0910
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250/50, BID for 2 weeks
Study: NCT04846621
Drug: Calcium channel blocker
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
Study: NCT01485770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks
Study: NCT03035708
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg BID
Study: NCT03779789
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day).
Study: NCT02689024
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
Study: NCT02689024
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
Study: NCT02689024
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
Study: NCT02689024
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
Study: NCT02689024
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
Study: NCT00811473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment once daily in the evening
Study: NCT03447132
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00134160
Drug: Calcium channel blockers (amlodipine, azelnidipine)
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
Study: NCT01622361
Drug: Adriamycin+Cyclophosphamide>Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~   * Route: by slow intravenous bolus~  * Schedule: every 3weeks for 4 cycle~2. Docetaxel 75mg/m2~   * Route: intravenous as per local practice~  * Schedule: every 3weeks for 4 cycle
Study: NCT04300114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules po. twice daily
Study: NCT02229747
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02229747
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02669433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, matching tablets
Study: NCT01868685
Drug: BYM338
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYM338
Study: NCT01868685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00296374
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg oral dose administered once daily for 52 weeks
Study: NCT00296374
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
Study: NCT01436500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water with 5% Dextrose
Study: NCT01765998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00308282
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Study: NCT00308282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
Study: NCT03975114
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any approved first line chemotherapy regimen at Investigators' choice
Study: NCT01996449
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
Study: NCT03389750
Drug: Intravenous Challenge Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of opioid drugs (oxycodone, oxymorphone, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
Study: NCT02211157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01411371
Drug: Medical treatment alone
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
Study: NCT02360501
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000mg/㎡,d1-14
Study: NCT02853578
Drug: Busonid (budesonide 200mcg and 400mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.
Study: NCT02157298
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet. Oral dose
Study: NCT03149419
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02845349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo comparator will be used in one subset of patients.
Study: NCT02737059
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg 4 times daily